Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...
GlobalData on MSN2d
Medtronic announces two-year trial outcomes of Evolut TAVRMedtronic has announced the SMART trial’s two-year outcomes of Evolut TAVR for aortic stenosis (AS) and small aortic annulus.
Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...
Zacks.com on MSN2d
Positive Trial Data on Evolut TAVR Likely to Support MDT StockAt the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.
Medtronic plc released positive results from a two-year trial of Evolut TAVR that demonstrated superior valve performance in patients with small aortic annuli. The SMall Annuli Randomized To Evolut or ...
Highlights,Evolut TAVR demonstrated significantly lower rates of bioprosthetic valve dysfunction (BVD) compared to SAPIEN at ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMa ...
Medtronic : Data Confirms Superior Valve Performance Of Evolut TAVR System In Small Annulus Patients
(RTTNews) - Medtronic plc (MDT ... comparative trial of transfemoral transcatheter aortic valve replacement (TAVR). In patients with aortic stenosis and a small aortic annulus, results showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback